Preliminary Phase 1 data showed statistically significant EASI improvement from Week 1, itch relief from Day 1, and additional topline readouts in atopic dermatitis and chronic spontaneous urticaria are expected in 1H 2027.
verifying reliability
No specialized terms available for this topic.